Compare GEO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | KNSA |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.9B |
| IPO Year | 1996 | 2018 |
| Metric | GEO | KNSA |
|---|---|---|
| Price | $31.74 | $75.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $39.67 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.5M | 430.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 225.00 |
| EPS | ★ 0.65 | 0.27 |
| Revenue | ★ $2,263,420,000.00 | $677,564,000.00 |
| Revenue This Year | $13.74 | $37.48 |
| Revenue Next Year | $9.99 | $17.87 |
| P/E Ratio | ★ $49.17 | $279.04 |
| Revenue Growth | 3.85 | ★ 60.09 |
| 52 Week Low | $12.51 | $35.53 |
| 52 Week High | $33.15 | $82.94 |
| Indicator | GEO | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | N/A |
| Support Level | $28.79 | N/A |
| Resistance Level | $32.47 | N/A |
| Average True Range (ATR) | 1.20 | 0.00 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 40.37 | 0.00 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.